Phil Nadeau, Ph.D.

Managing Director, Health Care - Biotechnology

Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen. He joined Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston.

Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University.

Get In Touch

Start a conversation with Phil Nadeau

Insights

Explore related thought leadership, reports, coverage and insights for Phil Nadeau.

Mar 19, 2020

COVID-19: Medical View from the Front Lines, Outlook for Vaccines and Drugs

Read More
Prescription drug tablets on a black surface
Ahead of the Curve®

Jan 29, 2020

2020 Drug Pricing Survey, 25th Annual

Read More
Ahead of the Curve®

Mar 8, 2019

The Medical Cannabis And Cannabinoid Landscape

Read More

Research Contacts

Our Research team is led by seasoned, entrepreneurial-minded individuals who are driven by a relentless curiosity to redefine expectations.

Meet Our People
Senior businessman handshaking with young woman in the office